Vivaldis Atosporin Cyclosporin 50mg Capsules for Dogs | Calcineurin Inhibitor Immunomodulator | Canine Atopic Dermatitis, Immune-Mediated Skin Disease & Chronic Pruritus | 1 Strip, 2 Strips & 4 Strips

PRESCRIPTION VETERINARY MEDICINE — For veterinary use only. Must be prescribed and dispensed by or under the supervision of a licensed veterinarian. Do not use in dogs with active neoplasia (cancer), uncontrolled infections, or known hypersensitivity to Cyclosporin. Use with caution in dogs with renal impairment — baseline and periodic renal function monitoring is required. Do not administer live vaccines during Cyclosporin therapy. Inform veterinarian of all concurrent medications — significant drug interactions exist. Keep out of reach of children. Store in a cool, dry place away from direct sunlight.

Vivaldis Atosporin Cyclosporin 50mg Capsules for Dogs

Vivaldis Atosporin 50mg is a prescription veterinary calcineurin inhibitor immunomodulatory capsule for dogs, containing Cyclosporin (Cyclosporine) 50mg per capsule. Indicated for the treatment of canine atopic dermatitis (CAD), chronic pruritus, and immune-mediated skin disease in dogs. The 50mg strength is suitable for small to medium breed dogs at the standard veterinary dose of 5mg/kg — confirm weight-based dosing and strip count per course from the Vivaldis Atosporin product label or veterinary prescription. Available in 1 Strip, 2 Strips, and 4 Strips pack sizes. Administer strictly as directed by a licensed veterinarian with appropriate monitoring.

Pack Sizes

• 1 Strip — ₹228.00: Single strip supply — confirm capsules per strip from product label
• 2 Strips: Two-strip supply — confirm price and capsule count from product label
• 4 Strips: Four-strip supply — best value for ongoing treatment; confirm price and capsule count from product label

Active Ingredient

• Cyclosporin (Cyclosporine A) — 50mg per capsule: Cyclic polypeptide calcineurin inhibitor; isolated from Tolypocladium inflatum (fungal origin); mechanism of action — forms a complex with cyclophilin (an intracellular immunophilin protein) inside T-lymphocytes; the Cyclosporin-cyclophilin complex binds to and inhibits calcineurin (a serine-threonine phosphatase); calcineurin inhibition prevents dephosphorylation and nuclear translocation of NFAT (Nuclear Factor of Activated T-cells); NFAT inhibition blocks transcription of pro-inflammatory cytokines including IL-2 (interleukin-2), IL-4, IL-5, IL-13, IFN-γ, and TNF-α; IL-2 suppression prevents T-lymphocyte activation, proliferation, and differentiation, reducing Th2-skewed immune responses central to atopic dermatitis pathophysiology; additionally inhibits mast cell degranulation, eosinophil activation, Langerhans cell function, and keratinocyte cytokine production; metabolised by hepatic CYP3A4 cytochrome P450 enzymes
• Capsule excipients — confirm from Vivaldis Atosporin product label

Therapeutic Class

• Prescription veterinary calcineurin inhibitor immunomodulatory oral capsule for dogs — canine atopic dermatitis (CAD), immune-mediated skin disease, and chronic pruritus management

Indications

• Canine atopic dermatitis (CAD) — reduction of pruritus and skin inflammatory lesions in dogs with confirmed atopic dermatitis where corticosteroid therapy is inadequate, poorly tolerated, or contraindicated for long-term use
• Immune-mediated skin disease — Cyclosporin-responsive dermatoses including perianal fistulae, sebaceous adenitis, pemphigus foliaceus, and other immune-mediated dermatological conditions (confirm specific indication with prescribing veterinarian)
• Chronic pruritus in dogs associated with allergic skin disease unresponsive to conventional antihistamine or essential fatty acid therapy

Dosage

• Administer strictly as directed by a licensed veterinarian — this is a prescription veterinary medicine
• Standard veterinary dosing: Cyclosporin 5mg/kg body weight once daily orally — the 50mg capsule is typically appropriate for dogs weighing approximately 5–10kg at standard dosing; confirm exact weight-based dose, dosing interval, and strip course duration from the Vivaldis Atosporin product label or veterinary prescription
• Dose tapering: once clinical remission is achieved (typically 4–8 weeks), dose frequency is often reduced to every other day or twice weekly under veterinary guidance to minimise long-term immunosuppression
• Administer on an empty stomach or consistently with food (food reduces absorption by approximately 20% — consistency of administration with or without food is important for predictable drug levels); confirm from product label
• Capsules should be swallowed whole; do not crush or open capsules

Contraindications

• Do not use in dogs with active neoplasia (cancer) — immunosuppressive activity may promote tumour progression
• Do not use in dogs with active, uncontrolled bacterial, fungal, or viral infections — treat infections fully before initiating therapy
• Do not use in dogs with known hypersensitivity to Cyclosporin or any capsule excipient
• Do not administer live vaccines during Cyclosporin therapy
• Use with caution in dogs with pre-existing renal impairment — Cyclosporin is nephrotoxic at high blood levels; baseline renal function testing (BUN, creatinine, SDMA, urinalysis) required before initiation and periodically during therapy
• Use with caution in dogs with hepatic disease — hepatic impairment may increase plasma Cyclosporin exposure

Drug Interactions (inform veterinarian of all concurrent medications)

• Ketoconazole / Fluconazole (azole antifungals): CYP3A4 inhibitors — significantly increase plasma Cyclosporin levels (up to 3×); intentional low-dose co-administration is a recognised dose-sparing strategy but requires careful renal and drug level monitoring
• Phenobarbital / Rifampicin: CYP3A4 inducers — significantly reduce plasma Cyclosporin levels; dose adjustment may be required
• NSAIDs (meloxicam, carprofen): Increased nephrotoxicity risk; use with caution with regular renal function monitoring
• Nephrotoxic drugs (aminoglycoside antibiotics, amphotericin B): Additive nephrotoxicity risk; avoid concurrent use where possible
• Other immunosuppressants (corticosteroids, azathioprine): Additive immunosuppression; increased opportunistic infection risk

Monitoring Requirements

• Baseline renal function (BUN, creatinine, SDMA, urinalysis) and hepatic function (ALT, ALP) before initiating therapy
• Periodic renal and hepatic function monitoring during long-term therapy as directed by veterinarian
• Monitor for opportunistic infections (bacterial skin infections, Malassezia overgrowth, Toxoplasma gondii reactivation) during therapy
• Monitor for gastrointestinal adverse effects (vomiting, diarrhoea, anorexia) particularly during initial weeks

Safety Information

• Prescription veterinary medicine — must be prescribed and dispensed by or under the supervision of a licensed veterinarian
• Cyclosporin is a systemic immunosuppressant — use lowest effective dose and taper to lowest effective frequency under veterinary guidance
• Gingival hyperplasia and papillomatosis may develop during long-term therapy — inform veterinarian if oral or skin papilloma-like lesions appear
• Toxoplasma gondii reactivation risk in seropositive dogs during immunosuppression — discuss with veterinarian
• Not for human use — keep out of reach of children; wash hands after handling capsules
• Store in a cool, dry place away from direct sunlight; keep in original packaging